To Top

Search By Topic

Roundtable

25 Articles available

Roundtable

Q: What Role has M&A Played in your Company’s Growth?

PAP-Q4-17-RT-001

Roundtable

Q: How do you Address Operational Excellence as an Institution?

PAP-Q4-17-RT-002

Roundtable

Q: Looking forward, what technologies do you anticipate having the greatest impact in 2018?

PAP-Q4-17-RT-002

Roundtable

Q: What do you see as being the most innovative technologies introduced in 2017? Why were they important? What impacts did they have?

PAP-Q4-17-RT-001

Roundtable

Q: How important are international partnerships (with sponsor firms, service providers, engineering firms, equipment vendors, raw material suppliers, etc.) to your success?

PAP-Q3-17-RT-001

Biologic

Q: If You Could Have One Piece of Biologic Manufacturing Equipment Improved, What Would It Be and Why?

PAP-Q2-17-RT-001

Roundtable

Q: How is Growth in the Biosimilars Market Impacting the Development of New Biologics Manufacturing Equipment Technologies?

PAP-Q2-17-RT-003

Roundtable

Q: Has Downstream Processing Technology Caught up with the Significantly Higher Titers Coming Out of the Current Upstream Process? If No, What Issues Remain?

PAP-Q2-17-RT-004

Roundtable

Q: What is the Most Significant Recent Advancement in Downstream Bioprocessing Technology? Why is it so Important?

PAP-Q2-17-RT-002

Q: How is the Need to Provide Local Drug-Product Supply in Multiple Regions Around the World Impacting Pharmaceutical Manufacturing Facility and Equipment Design?

PAP-Q1-17-RT-002

CRO

Q: What Do CROs/CDMOs Need to Do to Ensure That They Provide Effective Global Support but with Locally Oriented Services?

PAP-Q1-17-RT-001

Excipients

Q: What are the Greatest Challenges Drug Manufacturers Face When Working to Meet the New Requirements for Excipient Supply Chain Security?

PAP-Q1-17-RT-006

Cloud

Q: What Challenges are Associated with Implementing Cloud Computing within CROs/CDMOs?

PAP-Q1-17-RT-004

Cloud

Q: What Impact Do You Think the Move to Cloud Computing Will Have on the Ability of Contract Service Organizations to Better Meet the Needs of Their Customers?

PAP-Q1-17-RT-003

CDMO

Q: What New Technology Introduced Within the Last Year Have You Found to Have the Most Impact on Your Business?

PAP-Q04-16-RT-001

CDMO

Q: What is Your Perception of the State of Serialization in Your Sector of the Pharma Industry?

PAP-Q04-16-RT-003

CDMO

Q: What Are You Doing to Become a Premier Outsourcing Partner in the Context of FDA’s Recent Shift to a Focus on Quality Culture Rather than Just Metrics?

PAP-Q04-16-RT-002

The FDA Recently Validated a Continuous Manufacturing Pharma Process Line—What Do You Think This Means for the Future?

PAP-Q03-16-RT-001

Q: With Respect to Supplier-Partner Relationships, What is Your Preferred Collaboration Model?

PAP-Q03-16-RT-003

Q: What Have You Found to be the Greatest Benefit from Close Collaboration Partnership Models?

PAP-Q03-16-RT-005

In Close Supplier-Partner Relationships, What Pitfalls Do You Try to Avoid? How Close is Too Close?

PAP-Q03-16-RT-004

Q: When it Comes to Processing, What Technology Will Have the Most Impact on Pharma Processing Over the Next 10 Years?

PAP-Q03-16-RT-002

Bioavailability: What Are Your Thoughts On Enhancing Bioavailability With Novel Technologies?

PAP-Q02-16-RT-001

Antibody-Drug Conjugate: Do We Understand The Capital Investment In Our Staff?

PAP-Q02-16-RT-003

Biosimilars: Are We on the Edge of a New Era of Biologics?

PAP-Q02-16-RT-002